Noofambar 2021: Maamulka Cuntada iyo Dawooyinka ayaa oggolaaday atezolizumab (Tecentriq, Genentech, Inc.) for adjuvant treatment in patients with stage II to IIIA non-small cell lung cancer (NSCLC) whose tumours contain PD-L1 expression on less than 1% of tumour cells, as assessed by an FDA-approved test.
VENTANA PD-L1 (SP263) Assay (Ventana Medical Systems, Inc.) sidoo kale waxaa oggolaaday FDA maanta sidii qalab ogaanshaha saaxiibka ah oo loogu talagalay xulashada bukaannada NSCLC ee daaweynta adjuvant ee Tecentriq.
Badbaadinta cudur-la'aanta (DFS) waxay ahayd cabbirka natiijada waxtarka muhiimka ah, sida uu go'aamiyay baaraha ee dadweynaha falanqaynta waxtarka aasaasiga ah (n=476) ee bukaannada qaba marxaladda II-IIIA NSCLC oo leh PD-L1 muujinta 1% ee unugyada burooyinka ( PD-L1 1% TC). Gacanta atezolizumab, dhexdhexaadinta DFS lama gaarin (95 boqolkiiba CI: 36.1, NE) marka la barbar dhigo bilaha 35.3 (95 boqolkiiba CI: 29.0, NE) ee gacanta BSC (HR 0.66; 95 boqolkiiba CI: 0.50, 0.88; p= 0.004).
DFS HR waxay ahayd 0.43 koox-hoosaadyo hore loo cayimay oo koox-hoosaadeedka bukaanada qaba PD-L1 TC 50% heerka II-IIIA NSCLC (95 boqolkiiba CI: 0.27, 0.68). DFS HR waxay ahayd 0.87 daraasad koox-hoosaad ah oo sahamin ah oo bukaannada qaba PD-L1 TC 1-49 boqolkiiba heerka II-IIIA NSCLC (95 boqolkiiba CI: 0.60, 1.26).
Kordhinta aminotransferase aspartate, creatinine dhiigga, iyo alanine aminotransferase, iyo sidoo kale hyperkalemia, finan, qufac, hypothyroidism, pyrexia, daal / asthenia, murqo xanuun, neuropathy peripheral, arthralgia, iyo cuncun, ayaa ahaa kuwa ugu badan (boqolkiiba toban) falcelinta xun bukaanka qaata atezolizumab, oo ay ku jiraan cilladaha shaybaarka.
Tilmaamahan, qiyaasta atezolizumab ee lagu taliyey waa 840 mg labadii toddobaadba mar, 1200 mg saddexdii toddobaadba mar, ama 1680 mg afartii toddobaadba mar ilaa hal sano.
